Researchers looked at how the medication infliximab affects the gut microbiome in 242 children with inflammatory bowel disease. The study aimed to see if certain types of bacteria and metabolic pathways changed based on how well a child responded to the treatment.
Patients who responded well to the medicine often showed an increase in beneficial bacteria, such as Faecalibacterium, Subdoligranulum, and Bifidobacterium. In contrast, patients who did not respond well tended to have more of certain types of microbes like Gammaproteobacteria and Candida. The study also found that the treatment was linked to positive changes in how the body processes bile acids and short-chain fatty acids.
While many children saw clinical improvements with the medication, their overall microbial diversity did not always recover uniformly. Because these results come from a systematic review of existing data, they show a link between the medicine and specific gut bacteria rather than a guaranteed prediction for every patient. More research is needed to determine how these findings can help doctors choose the best treatment plans.
